BNP Paribas Financial Markets Sells 3,886 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

BNP Paribas Financial Markets trimmed its stake in SI-BONE, Inc. (NASDAQ:SIBN) by 3.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 102,556 shares of the company’s stock after selling 3,886 shares during the period. BNP Paribas Financial Markets owned 0.24% of SI-BONE worth $1,438,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. American Century Companies Inc. raised its stake in shares of SI-BONE by 11.0% in the 4th quarter. American Century Companies Inc. now owns 2,378,068 shares of the company’s stock valued at $33,341,000 after acquiring an additional 236,167 shares in the last quarter. Geode Capital Management LLC grew its holdings in SI-BONE by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 933,891 shares of the company’s stock valued at $13,097,000 after buying an additional 9,847 shares during the last quarter. Impax Asset Management Group plc grew its holdings in SI-BONE by 1.1% in the 4th quarter. Impax Asset Management Group plc now owns 766,761 shares of the company’s stock valued at $10,750,000 after buying an additional 8,240 shares during the last quarter. Pier Capital LLC grew its holdings in SI-BONE by 1.6% in the 4th quarter. Pier Capital LLC now owns 473,123 shares of the company’s stock valued at $6,633,000 after buying an additional 7,225 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in SI-BONE by 6.3% in the 4th quarter. Northern Trust Corp now owns 409,122 shares of the company’s stock valued at $5,736,000 after buying an additional 24,214 shares during the last quarter. 98.11% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on SIBN shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 target price on shares of SI-BONE in a report on Tuesday, May 6th. Truist Financial raised their target price on SI-BONE from $20.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, May 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $24.00 target price on shares of SI-BONE in a report on Tuesday, May 6th.

Insider Activity at SI-BONE

In other SI-BONE news, CFO Anshul Maheshwari sold 4,937 shares of the business’s stock in a transaction on Wednesday, May 7th. The stock was sold at an average price of $17.00, for a total value of $83,929.00. Following the transaction, the chief financial officer now owns 265,356 shares of the company’s stock, valued at approximately $4,511,052. The trade was a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Michael A. Pisetsky sold 3,128 shares of the business’s stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total value of $44,229.92. Following the completion of the transaction, the senior vice president now directly owns 244,878 shares in the company, valued at approximately $3,462,574.92. This represents a 1.26% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 55,153 shares of company stock valued at $935,040 in the last 90 days. 4.00% of the stock is owned by corporate insiders.

SI-BONE Price Performance

Shares of NASDAQ:SIBN opened at $19.79 on Monday. SI-BONE, Inc. has a 1-year low of $11.70 and a 1-year high of $20.05. The firm has a market capitalization of $843.35 million, a PE ratio of -21.51 and a beta of 0.82. The business’s 50 day moving average is $14.83 and its 200-day moving average is $15.04. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The company had revenue of $47.29 million for the quarter, compared to analyst estimates of $45.13 million. Sell-side analysts predict that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.